Skip to main content

Zymeworks Inc

For the period ended Mar 31, 2024. Filed May 2, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 2, 2024

ZYME$31.46+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(Expressed in thousands of U.S. dollars)

Three Months Ended March 31,
20242023
Cash flows from operating activities:
Net loss$(31,653)$(24,353)
Items not involving cash:
Depreciation of property and equipment1,0611,584
Amortization of intangible assets702679
Stock-based compensation expense3,5522,325
Amortization of operating lease right-of-use assets549637
Deferred income tax (recovery) expense(38)9
Change in fair value of contingent consideration liability(700)499
Unrealized foreign exchange gain(487)(298)
Changes in non-cash operating working capital:
Accounts receivable(11,468)(33,516)
Prepaid expenses and other current assets(227)(1,671)
Accounts payable and accrued liabilities2,284(28,266)
Operating lease liabilities(1,035)(820)
Deferred revenue and other consideration(259)—
Income taxes payable50—
Net cash used in operating activities(37,669)(83,191)
Cash flows from financing activities:
Issuance of common stock on exercise of stock options1,7431,516
Issuance of common stock through employee stock purchase plan386236
Finance lease payments(6)(14)
Net cash provided by financing activities2,1231,738
Cash flows from investing activities:
Purchases of marketable securities(66,509)(182,055)
Proceeds from marketable securities59,84744,219
Acquisition of property and equipment(185)(386)
Acquisition of intangible assets(469)—
Net cash used in investing activities(7,316)(138,222)
Effect of exchange rate changes on cash and cash equivalents119346
Net change in cash and cash equivalents(42,743)(219,329)
Cash and cash equivalents, beginning of period157,557400,912
Cash and cash equivalents, end of period$114,814$181,583
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.